Key to GPT's global development and commercialization strategy, Dr. Mark Moore was named CEO for GemPharmatech, LLC, a wholly owned subsidiary of GemPharmatech, Co., Ltd., responsible for all operations in the US and Europe.

Dr. Moore is a pioneer in the use of genetically modified mice for pharmaceutical and basic research and has worked in immunology, oncology, animal model construction, and gene editing.

Dr. Moore was co-founder and CSO of Deltagen, the first high-throughput gene KO and target development company and served as the first Executive Director of the International Mouse Phenotyping Consortium (IMPC).